The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-03. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
=== Addiction and tolerance === Though there is no evidence that ketamine can cause physical dependence, some people who regularly use it can develop an addiction to it. Animal experiments also confirm the risk of misuse. Additionally, the rapid onset of effects following insufflation may increase potential use as a recreational drug. The short duration of effects promotes bingeing. Ketamine tolerance rapidly develops, even with repeated medical use, prompting the use of higher doses. Some users have reported withdrawal symptoms, primarily anxiety, tremor, sweating, and palpitations, following the attempts to stop; however, these effects have never been objectively measured in the way that physical withdrawal symptoms from drugs like opioids or benzodiazepines have.
In 2000, it acquired Brazilian appliance maker Multibrás, owner of the brands Brastemp and Consul, including its stake in Embraco. In 2001, Inglis Ltd. changed its name to Whirlpool Canada. Whirlpool continues to market Inglis appliances to this day.
However, light intensity walking is an effective way to help control casual glucose level (CGL), but a minimum of 6000 steps must be achieved daily to have consistent effectiveness in controlling CGL.Nevertheless, there is no significant correlation between light intensity walking and HbA1c, therefore regular moderate intensity exercise is advised, specifically aerobic exercise has been proven to improve both fasting and postprandial blood glucose, insulin dosage, and insulin usage within the body. It is still contested which form of exercise/physical activity is best for pregnant women, yet some movement is better than no movement. Although exercise does not reduce the risk of developing GDM, it does help reduce some of the associated risks. When it comes to exercise in pregnant women who have GDM there is a decrease in the risk of having a newborn with macrosomia, decrease in maternal weight gain and a decrease in c-sections. Although exercise is not the cure for GDM, it does help pregnant women decrease any complications or risk factors that can arise from the disease. Self-monitoring can be accomplished using a handheld capillary glucose dosage system. Compliance with these glucometer systems can be low. There is not a lot of research into what target blood sugar levels should be for women with gestational diabetes, and targets recommended to women vary globally. Target ranges advised by the Australasian Diabetes in Pregnancy Society are as follows:
== Molecular pathology == The majority of mammals possess six different actin genes. Of these, two code for the cytoskeleton (ACTB and ACTG1) while the other four are involved in skeletal striated muscle (ACTA1), smooth muscle tissue (ACTA2), intestinal muscles (ACTG2) and cardiac muscle (ACTC1). The actin in the cytoskeleton is involved in the pathogenic mechanisms of many infectious agents, including HIV. The vast majority of the mutations that affect actin are point mutations that have a dominant effect, with the exception of six mutations involved in nemaline myopathy. This is because in many cases the mutant of the actin monomer acts as a "cap" by preventing the elongation of F-actin.
Sources: en.wikipedia.org
The Mediterranean seeps appear to represent a rich habitat characterized by megafauna species richness (e.g., gastropods) or the exceptional size of some species such as sponges (Rhizaxinella pyrifera) and crabs (Chaceon mediterraneus), compared with their background counterparts. This contrasts with the low macro- and mega-faunal abundance and diversity of the deep eastern Mediterranean. Seep communities in the Mediterranean that include endemic chemosynthetic species and associated fauna differ from the other known seep communities in the world at the species level but also by the absence of the large-size bivalve genera Calyptogena or Bathymodiolus. The isolation of the Mediterranean seeps from the Atlantic Ocean after the Messinian crisis led to the development of unique communities, which are likely to differ in composition and structure from those in the Atlantic Ocean. Further expeditions involved quantitative sampling of habitats in different areas, from the Mediterranean Ridge to the eastern Nile deep-sea fan. Cold seeps discovered in the Sea of Marmara in 2008 have also revealed chemosynthesis-based communities that showed a considerable similarity to the symbiont-bearing fauna of eastern Mediterranean cold seeps.
== Types == Pumps can be broadly categorized according to three techniques: positive displacement, momentum transfer, and entrapment. Positive displacement pumps use a mechanism to repeatedly expand a cavity, allow gases to flow in from the chamber, seal off the cavity, and exhaust it to the atmosphere. Momentum transfer pumps, also called molecular pumps, use high-speed jets of dense fluid or high-speed rotating blades to knock gas molecules out of the chamber. Entrapment pumps capture gases in a solid or adsorbed state; this includes cryopumps, getters, and ion pumps. Positive displacement pumps are the most effective for low vacuums. Momentum transfer pumps, in conjunction with one or two positive displacement pumps, are the most common configuration used to achieve high vacuums. In this configuration the positive displacement pump serves two purposes. First, it obtains a rough vacuum in the vessel being evacuated before the momentum transfer pump can be used to obtain the high vacuum, as momentum transfer pumps cannot start pumping at atmospheric pressures. Second, the positive displacement pump backs up the momentum transfer pump by evacuating to low vacuum the accumulation of displaced molecules in the high vacuum pump. Entrapment pumps can be added to reach ultrahigh vacuums, but they require periodic regeneration of the surfaces that trap air molecules or ions. Due to this requirement their available operational time can be unacceptably short in low and high vacuums, thus limiting their use to ultrahigh vacuums.
===== MeSH D08.811.913.050 – acyltransferases (EC 2.3) ===== MeSH D08.811.913.050.080 – acetyl-CoA C-acyltransferase MeSH D08.811.913.050.134 – acetyltransferases MeSH D08.811.913.050.134.029 – acyl-carrier protein s-acetyltransferase MeSH D08.811.913.050.134.060 – acetyl-CoA C-acetyltransferase MeSH D08.811.913.050.134.105 – amino-acid n-acetyltransferase MeSH D08.811.913.050.134.150 – carnitine O-acetyltransferase MeSH D08.811.913.050.134.170 – chloramphenicol o-acetyltransferase MeSH D08.811.913.050.134.180 – choline o-acetyltransferase MeSH D08.811.913.050.134.310 – dihydrolipoyllysine-residue acetyltransferase MeSH D08.811.913.050.134.375 – glucosamine 6-phosphate n-acetyltransferase MeSH D08.811.913.050.134.407 – histone acetyltransferases MeSH D08.811.913.050.134.440 – p300-CBP coactivator family MeSH D08.811.913.050.134.440.249 – creb-binding protein MeSH D08.811.913.050.134.440.600 – e1a-associated p300 protein MeSH D08.811.913.050.134.700 – phosphate acetyltransferase MeSH D08.811.913.050.134.850 – serine O-acetyltransferase MeSH D08.811.913.050.170 – acyl-carrier protein s-malonyltransferase MeSH D08.811.913.050.173 – 1-acylglycerol-3-phosphate O-acyltransferase MeSH D08.811.913.050.175 – 1-acylglycerophosphocholine O-acyltransferase MeSH D08.811.913.050.200 – aminoacyltransferases MeSH D08.811.913.050.200.400 – gamma-glutamylcyclotransferase MeSH D08.811.913.050.200.500 – gamma-glutamyltransferase MeSH D08.811.913.050.200.700 – peptidyl transferases MeSH D08.811.913.050.200.800 – transglutaminases MeSH D08.811.913.050.200.800.300 – factor xiiia MeSH D08.811.913.050.276 – 5-aminolevulinate synthetase MeSH D08.811.913.050.294 – arylalkylamine n-acetyltransferase MeSH D08.811.913.050.313 – arylamine N-acetyltransferase MeSH D08.811.913.050.331 – atp citrate (pro-s)-lyase MeSH D08.811.913.050.350 – carnitine acyltransferases MeSH D08.811.913.050.350.170 – carnitine O-acetyltransferase MeSH D08.811.913.050.350.200 – carnitine o-palmitoyltransferase MeSH D08.811.913.050.368 – citrate (Si)-synthase MeSH D08.811.913.050.387 – diacylglycerol o-acyltransferase MeSH D08.811.913.050.425 – glycerol-3-phosphate O-acyltransferase MeSH D08.811.913.050.600 – homoserine O-succinyltransferase MeSH D08.811.913.050.612 – hydroxymethylglutaryl-CoA synthase MeSH D08.811.913.050.614 – 2-isopropylmalate synthase MeSH D08.811.913.050.618 – malate synthase MeSH D08.811.913.050.622 – 3-oxoacyl-(acyl-carrier-protein) synthase MeSH D08.811.913.050.625 – phosphatidylcholine-sterol O-acyltransferase MeSH D08.811.913.050.646 – retinol O-fatty-acyltransferase MeSH D08.811.913.050.668 – serine C-palmitoyltransferase MeSH D08.811.913.050.712 – sphingosine N-acyltransferase MeSH D08.811.913.050.799 – sterol O-acyltransferase
=== Jonah Atterbury === Jonah Atterbury (Kal Penn) is the co-founder and CEO of Tender, which he started with his college friend Whitney Halberstram. Once an ambitious business school graduate, Jonah has since devolved into an irresponsible and inattentive CEO, addicted to partying, drugs, and pornography, and frequently showing up intoxicated to the office. He clashes with Whitney over the latter's desire to pivot Tender away from lucrative "alternative merchants" like porn and gambling and towards banking. Whitney and the Tender board soon use behavioral clauses in Jonah's contract to remove him as CEO, citing his inappropriate behavior, poor hygiene, and misuse of company funds; Whitney takes over in the interim. Jonah is later contacted by Sweetpea Golightly, who is investigating Tender's shady finances as part of a short; a vengeful Jonah, who is suing Whitney for defamation, emails Sweetpea a trove of subpoenaed internal Tender emails that she uses to uncover a connection to Accra. After Tender's stock plummets following revelations of its fraud, Whitney attempts to contact Jonah, who rebuffs him.
=== Mayor of Nuevo Cuscatlán === In 2011, Bukele announced that he would enter politics as a member of the FMLN to break out of "his comfort zone" ("su zona de confort") as a businessman. Officially joining the party in 2012, he campaigned for the mayoralty of Nuevo Cuscatlán, a municipality in the department of La Libertad, part of the San Salvador metropolitan area. Bukele's campaign was supported by the Democratic Change party. He was elected mayor of Nuevo Cuscatlán in March 2012 with 51.67 percent of the vote, defeating primary challenger Tomás Rodríguez of the Nationalist Republican Alliance (ARENA). Bukele took office on 1 May 2012 as the country's youngest mayor. Bukele created a scholarship program for youths in the municipality, donating his $2,000 salary to fund the program. In August 2014, Bukele launched Sphere PM, a project that launched a high-altitude balloon to an altitude of 100,000 feet (30,000 m) and took pictures of El Salvador. He stated that Sphere PM's goal was to promote education in science and technology to dissuade the municipality's youth from crime. Bukele spoke at the United Nations headquarters about projects he had undertaken as mayor of Nuevo Cuscatlán as part of the November 2014 World Cities Day. In January 2015, he inaugurated a $1.7 million boulevard connecting Nuevo Cuscatlán with Huizúcar and Antiguo Cuscatlán. Bukele did much of his mayoral work with funding from ALBA Petróleos, owned by the Venezuelan oil company PDVSA.
Sources: en.wikipedia.org
=== July === July 1 Trade Representative Jamieson Greer announces that the US will not renew the USMCA free trade agreement signed during Trump's first administration. Trump takes his first flight in the new Air Force One, which was gifted by Qatar. Three American soldiers are injured and one soldier is missing after their MH-60S Seahawk helicopter went down in the Arabian Sea. July 3 2026 North American heat wave: Heat waves are reported across the eastern and central United States, with Independence Day celebrations cancelled or postponed including the Great American State Fair on the National Mall. Around 23 U.S. states are placed under heat warnings by the National Weather Service. A man dies after setting himself on fire outside the UN in New York, with activists and reports identifying him as a pro-Tibet advocate. Democrat Harry Benton resigns from the Illinois House of Representatives after allegations of misconduct.
Various signalling pathways, as FGF, WNT and TGF-β pathways, regulate the processes involved in embryogenesis. FGF (Fibroblast Growth Factor) ligands bind to receptors tyrosine kinase, FGFR (Fibroblast Growth Factor Receptors), and form a stable complex with co-receptors HSPG (Heparan Sulphate Proteoglycans) that will promote autophosphorylation of the intracellular domain of FGFR and consequent activation of four main pathways: MAPK/ERK, PI3K, PLCγ and JAK/STAT.
Hox genes play a massive role in some amphibians and reptiles in their ability to regenerate lost limbs, especially HoxA and HoxD genes. If the processes involved in forming new tissue can be reverse-engineered into humans, it may be possible to heal injuries of the spinal cord or brain, repair damaged organs and reduce scarring and fibrosis after surgery. Despite the large conservation of the Hox genes through evolution, mammals and humans specifically cannot regenerate any of their limbs. This raises a question as to why humans which also possess an analog to these genes cannot regrow and regenerate limbs. Beside the lack of specific growth factor, studies have shown that something as small as base pair differences between amphibian and human Hox analogs play a crucial role in human inability to reproduce limbs. Undifferentiated stem cells and the ability to have polarity in tissues is vital to this process.
4-Aminosalicylic acid was first synthesized by Seidel and Bittner in 1902. It was rediscovered by the Swedish chemist Jörgen Lehmann upon the report that the tuberculosis bacterium avidly metabolized salicylic acid. Lehmann first tried PAS as an oral TB therapy late in 1944. The first patient made a dramatic recovery. The manner in which Lehmann discovered the TB indication for PAS was salient in the history of drug discovery because it was a rare example in which a person mentally postulated the exact molecule for a drug based on their acquired knowledge of the biochemical behaviour of an analogue of the molecule. The drug proved better than streptomycin, which had nerve toxicity and to which TB could easily develop resistance. In 1948, researchers at Britain's Medical Research Council demonstrated that combined treatment with streptomycin and PAS was superior to either drug alone, and established the principle of combination therapy for tuberculosis. 4-Aminosalicylic acid has many names including para-aminosalicylic acid, p-aminosalicylic acid, 4-ASA, and simply P.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.